DBV Technologies S.A. (DBVT): Total Liabilities
$64.95M
As of 2025-12-31
$62.80M
As of 2026-06-30
+7.6%
3-year compound annual growth
-0.5%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $64.95M | +69.7% | 2026-03-26, Balance as of period end |
| 2024-12-31 | $38.27M | -10.6% | 2026-03-26, Balance as of period end |
| 2023-12-31 | $42.80M | -17.8% | 2025-04-11, Balance as of period end |
| 2022-12-31 | $52.06M | +9.7% | 2024-03-07, Balance as of period end |
| 2021-12-31 | $47.45M | -28.9% | 2023-03-02, Balance as of period end |
| 2020-12-31 | $66.75M | -15.0% | 2022-03-09, Balance as of period end |
| 2019-12-31 | $78.54M | n/a | 2021-03-17, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| DBV Technologies S.A. (DBVT) | 2025-12-31 | $64.95M | +69.7% |
| Zeo ScientifiX, Inc. (ZEOX) | 2025-10-31 | $2.95M | -10.5% |
| Prime Medicine, Inc. (PRME) | 2025-12-31 | $221.87M | +53.7% |
| Ocugen, Inc. (OCGN) | 2025-12-31 | $55.68M | +5.4% |
| CG Oncology, Inc. (CGON) | 2025-12-31 | $38.99M | +82.0% |
| CRISPR Therapeutics AG (CRSP) | 2025-12-31 | $343.43M | +10.8% |
| Surrozen, Inc. (SRZN) | 2025-12-31 | $286.49M | +310.2% |
| Curis Inc (CRIS) | 2025-12-31 | $14.50M | -69.3% |
| Taysha Gene Therapies, Inc. (TSHA) | 2025-12-31 | $96.38M | +8.5% |
Compare DBVT, ZEOX, PRME, OCGN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗